Therapeutic implications of interleukin-10 in surgical disease

被引:70
作者
Selzman, CH
Shames, BD
Miller, SA
Pulido, EJ
Meng, XZ
McIntyre, RC
Harken, AH
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Surg, Denver, CO 80262 USA
[2] Vet Affairs Hosp, Denver, CO 80262 USA
来源
SHOCK | 1998年 / 10卷 / 05期
关键词
D O I
10.1097/00024382-199811000-00001
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
Pharmacological therapy of surgical disease often involves manipulating the physiologic balance between pro; and anti-inflammatory responses. Many agents target only one aspect of the inflammatory cascade. Originally identified as a protein elaborated by T-lymphocytes, IL-IO appears to globally inhibit cytokine production. the purpose of this manuscript is to examine the immunomodulatory and anti-inflammatory effects of interleukin-10 (IL-10) in an attempt to define the clinical utility of IL-10, both as a marker of and as a therapeutic strategy for intervention in inflammatory and immune-mediated diseases. IL-10 is elaborated from multiple sources and has diverse cellular effects to regulate immune and inflammatory responses. Accumulating evidence suggests that the anti-inflammatory influence of IL-10 Observed at the cellular level may be manipulated to impact the immune and inflammatory-mediated responses associated with injury and sepsis, gastrointestinal and cardiovascular disease, and transplantation. In conclusion, IL-10 is an important mediator of immune and anti-inflammatory responses in surgical disease and, as such, has therapeutic promise as an immunomodulator and as an anti-inflammatory agent.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 156 条
[1]
Aderka Dan, 1996, Cytokine and Growth Factor Reviews, V7, P231, DOI 10.1016/S1359-6101(96)00026-3
[2]
Relative production of tumour necrosis factor a and interleukin 10 in adult respiratory distress syndrome [J].
Armstrong, L ;
Millar, AB .
THORAX, 1997, 52 (05) :442-446
[3]
AZZAWI M, 1995, J HEART LUNG TRANSPL, V14, P519
[4]
The IFN gamma receptor: A paradigm for cytokine receptor signaling [J].
Bach, EA ;
Aguet, M ;
Schreiber, RD .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :563-&
[5]
SAFETY AND EFFICACY OF THERAPEUTIC MONOCLONAL-ANTIBODIES IN CLINICAL-THERAPY [J].
BACH, JF ;
FRACCHIA, GN ;
CHATENOUD, L .
IMMUNOLOGY TODAY, 1993, 14 (09) :421-425
[6]
The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[7]
LIPOPOLYSACCHARIDE-INDUCED INTERLEUKIN-10 IN MICE - ROLE OF ENDOGENOUS TUMOR-NECROSIS-FACTOR-ALPHA [J].
BARSIG, J ;
KUSTERS, S ;
VOGT, K ;
VOLK, HD ;
TIEGS, G ;
WENDEL, A .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (10) :2888-2893
[8]
Berman RM, 1996, J IMMUNOL, V157, P231
[9]
Interleukin-6 in the injured patient marker of injury or mediator of inflammation? [J].
Biffl, WL ;
Moore, EE ;
Moore, FA ;
Peterson, VM .
ANNALS OF SURGERY, 1996, 224 (05) :647-664
[10]
The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1 beta interleukin-1 receptor antagonist and interleukin-10 in human volunteers [J].
Bleeker, MWP ;
Netea, MG ;
Kullberg, BJ ;
VandervenJongekrijg, J ;
VanderMeer, JFM .
IMMUNOLOGY, 1997, 91 (04) :548-552